FDA Clears Dispatch Bio’s Unusual Two-Step Immunotherapy for Solid Tumors
PHILADELPHIA, PA & SAN FRANCISCO, CA — Dispatch Bio said the U.S. Food and Drug Administration has cleared its Investigational New Drug application for DISP-10, allowing the company to initiate …
FDA Clears Dispatch Bio’s Unusual Two-Step Immunotherapy for Solid Tumors Read More